GBT


Global Blood Therapeutics (GBT) Gets Attention of FDA As Well As Investors

Monday morning Global Blood Therapeutics (GBT) announced the FDA has agreed to GBT’s plan to file for accelerated approval of voxelotor, a unique …

Global Blood Therapeutics (GBT): Now That’s a Go Ahead!

On a day like today, when the entire stock market is under pressure, you must have done something right to see your stock …

Top Analyst Shines Light on Global Blood Therapeutic (GBT) Following Phase 2a Results in SCD

Global Blood Therapeutics (NASDAQ:GBT) investors got cold feet today, sending shares tumbling nearly 17%. The reason?

Global Blood Therapeutics Inc (GBT): Breakthrough Designation for Lead Asset Has This Top Analyst Hopeful on Voxelotor’s Prospects

One of Wall Street’s best analysts believes “the first cut” of data evaluating GBT’s sickle cell disease drug is looking pretty good right now.

Healthcare Stocks Breakout: Pain Therapeutics, Inc. (PTIE), Global Blood Therapeutics Inc (GBT)

Pain Therapeutics to try again with REMOXY NDA Investors love biotech stocks for the lottery ticket-like returns they can offer if a company …

Global Blood Therapeutics Inc (GBT): Despite Reports of Two Patient Deaths, This Top Analyst Remains Bullish

Why patient deaths don’t necessarily scuttle Global Blood’s chances for voxelotor’s clinical success.

Roth Capital’s Focus Pick: Global Blood Therapeutics Inc (GBT)

Global Blood Therapeutics Inc (NASDAQ:GBT) shares rose about 9% today after the biopharmaceutical company initiated a Phase 1 trial evaluating GBT440 in healthy volunteers under hypoxic …

Roth Capital Maintains Positive Stance on Global Blood Therapeutics Inc (GBT) Following Updated Clinical Results for GBT440

Roth Capital analyst Mark Breidenbach is out today with a favorable report on shares of Global Blood Therapeutics Inc (NASDAQ:GBT), after the company provided updated …